Kevin Holden, PhD

Head of Science, Synthego

Kevin Holden, PhD is Head of Science at Synthego in Redwood City, California. A senior member of a team responsible for developing platforms that deliver high-quality, scalable CRISPR genome engineering solutions, he helps to define Synthego’s scientific strategy and innovation through collaborative engagement with key opinion leaders in the genome engineering community. He has over 15 years of biotechnology experience with a focus in synthetic biology and genome engineering.

Cell and Gene Therapy 2023

This inaugural event will showcase recent advances in the development of cell and gene therapies and the opportunities they provide for the treatment of disease and injury. Focus will be given to cancer immunotherapies and vaccines, stem cells, vector technologies and examples of genetic modification to treat a range of conditions.